Integra LifeSciences Holdings Corporation — Q2 2014 Form 10-Q
Business context and reporting period
Integra is a global medical technology company serving neurosurgery, orthopedics, spine, extremities, reconstructive surgery and general surgery markets. The filing covers the three and six months ended June 30, 2014. Results include the January 15, 2014 acquisition of Confluent Surgical, whose surgical sealant and adhesion barrier products strengthened the neurosurgery portfolio.
Financial performance and liquidity
| Metric | Q2 2014 | Q2 2013 | Six months 2014 | Six months 2013 |
|---|---|---|---|---|
| Revenue | $231.4 million | $205.5 million | $446.4 million | $402.2 million |
| Gross profit | $144.4 million | $123.7 million | $277.1 million | $240.8 million |
| Gross margin | 62.4% | 60.2% | 62.1% | 59.9% |
| Operating income | $12.4 million | $5.6 million | $21.1 million | $3.4 million |
| Net income (loss) | $4.8 million | $1.5 million | $7.0 million | $(4.5) million |
| Diluted EPS | $0.15 | $0.05 | $0.21 | $(0.16) |
| Operating cash flow | Not separately provided | Not separately provided | $27.6 million | $10.8 million |
Second-quarter revenue increased approximately 13%, while first-half revenue increased approximately 11%. Approximate net margins were 2.1% in Q2 and 1.6% for the first half. Segment growth was led by U.S. Neurosurgery, which increased 45% in Q2 and 42% for the first half, primarily due to Confluent Surgical’s DuraSeal sales and recovery from 2013 product recalls. International revenue increased 9% in Q2 and 10% for the first half. U.S. Instruments declined 4% in Q2 and 3% for the first half.
Cash and cash equivalents were $137.2 million at June 30, 2014, compared with $120.6 million at December 31, 2013. Working capital was $437.3 million. Six-month investing cash outflow was $255.7 million, including $235.0 million for the Confluent Surgical acquisition and $20.7 million of capital expenditures. Financing cash inflow was $244.2 million, principally from borrowings used to fund the acquisition.
Debt included $421.9 million outstanding under the Senior Credit Facility and $230.0 million principal amount of 1.625% convertible notes due December 2016. Approximately $178.1 million remained available under the credit facility at June 30. The company was in compliance with its debt covenants. No share repurchases occurred during the period, and $75.0 million remained authorized.
Material changes versus the prior comparable period
- Gross margin improved by 220 basis points in Q2 and 220 basis points for the first half, reflecting higher sales of DuraSeal, skin and wound products, and Duragen, as well as lower recall and manufacturing remediation costs.
- Operating income improved substantially despite higher selling, general and administrative expenses, integration costs, severance, ERP-related expenses and other special charges.
- The company returned to profitability for the first half, compared with a prior-year loss.
- 2013 comparisons were retrospectively adjusted for a change in accounting for the medical device excise tax. The tax is now recorded in selling, general and administrative expense when the first U.S. sale occurs.
- Confluent Surgical added approximately $105.3 million of goodwill and $239.8 million of technology product rights to the preliminary acquisition allocation. The purchase price allocation remained preliminary.
- The company incurred $17.6 million of identified special charges in Q2 and $33.5 million in the first half, including ERP implementation, structural optimization, severance, acquisition-related charges and non-cash convertible debt interest.
Guidance, outlook, commentary and risks
- Management expects full-year 2014 gross margin of 61% to 62%, supported by product mix and manufacturing yield improvements.
- Research and development spending is expected to be approximately 6% of full-year revenue.
- The expected full-year effective tax rate is approximately 23% to 24%.
- 2014 capital expenditures are expected to be $45 million to $50 million, including regenerative medicine capacity, ERP implementation, facility support and orthopedic instrument kits. Inventory is also expected to build ahead of facility consolidations.
- The company completed a diabetic foot ulcer clinical trial in July 2014 and expected to submit data to the FDA by year-end 2014, with potential commercialization targeted for mid-2016 subject to regulatory and reimbursement developments.
- FDA remediation activities continued at the Añasco, Puerto Rico and Andover, England facilities. Related costs declined materially from 2013, but additional expenses were expected during 2014.
- A U.S. Attorney’s Office investigation concerning alleged improper billing by three sales representatives remained unresolved. The company stated it was cooperating and was not a subject or target at the filing date.
- A licensor indicated that an international extremities product license would terminate October 20, 2014. Products sold under the license generated approximately $5.5 million of 2013 revenue; potential claims and the ultimate financial effect were not determinable.
- On July 2, 2014, after quarter-end, the company amended and restated its credit facility, increasing total availability to $900 million, extending maturity to July 2, 2019, and borrowing approximately $422 million to refinance prior borrowings.
- Key risks include leverage and the need to refinance or extend the 2016 convertible notes, variable interest rates, foreign currency exposure, acquisition integration, product quality and regulatory compliance, litigation and contingent consideration.
Important facts for investors to verify
- Assess the sustainability of revenue and margin gains attributable to Confluent Surgical, DuraSeal and recovery from the 2013 recalls.
- Reconcile reported earnings with the $33.5 million of first-half special charges and determine which expenses may recur.
- Review post-quarter-end debt balances, covenant requirements, refinancing needs and the maturity of the 2016 convertible notes.
- Monitor FDA remediation, product quality, regulatory submissions and the potential diabetic foot ulcer commercialization timeline.
- Track the U.S. Attorney investigation and the disputed international license termination, including any claims or inventory consequences.
- Evaluate working-capital requirements, particularly the $17.4 million first-half use of cash for inventory and planned facility consolidations.